This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Chemed (CHE) Q1 Earnings Miss Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ATI Physical Therapy, Inc. (ATIP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of -351.43% and 1.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Tops Q2 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 28.04% and 2.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ATI Physical Therapy, Inc. (ATIP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of -87.50% and 4.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 3rd
by Zacks Equity Research
ILLM, ATIP and AOMR have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2023.
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ATI Physical Therapy, Inc. (ATIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 26th
by Zacks Equity Research
KERN, ILLM and ATIP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2023.
New Strong Sell Stocks for April 4th
by Zacks Equity Research
ATY, ASYS and ATIP have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
New Strong Sell Stocks for March 31st
by Zacks Equity Research
ATY, ATIP and ASMIY have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2023.
New Strong Sell Stocks for March 28th
by Zacks Equity Research
ATY, ATIP and APA have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2023.
Strength Seen in LifeStance Health (LFST): Can Its 5.5% Jump Turn into More Strength?
by Zacks Equity Research
LifeStance Health (LFST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
ATI Physical Therapy, Inc. (ATIP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of 0% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ATI Physical Therapy, Inc. (ATIP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of -42.86% and 3.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will ATI Physical Therapy, Inc. (ATIP) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why ATI Physical Therapy, Inc. (ATIP) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is ATI Physical Therapy, Inc. (ATIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ATI Physical Therapy, Inc. (ATIP) and Baxter International (BAX) have performed compared to their sector so far this year.